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doi:10.1016/j.jfma.2011.11.009Background/Purpose: A multicenter study (NCT00449670) conducted across Taiwan, Singa-
pore, Hong Kong and Thailand evaluated the safety and manufacturing consistency of four
formulations of an AS03A-adjuvanted H5N1 vaccine in terms of immune response against the
vaccine-homologous strain (A/Vietnam/1194/2004). This manuscript presents data from the
Taiwanese population.
Methods: A total of 400 individuals, aged 18e60 years, were randomized into six groups
(2:2:2:2:1:1 ratio) to receive two doses (21 days apart) of one of the four adjuvanted formu-
lations (H5N1-AS03A-groups) or one of the two nonadjuvanted formulations (H5N1-DIL-groups).
Blood samples collected before vaccination (Day 0) and 21 days after each vaccine dose were
analyzed using hemagglutination inhibition (HI) assay. Adverse events were recorded.
Results: All four AS03A-adjuvanted formulations induced comparable immune responses
against the A/Vietnam/1194/2004 strain; following the second dose, immune response in
terms of HI antibodies was higher in the H5N1-AS03A-groups {seroprotection rateZ 91.6%
[95% confidence interval (CI): 87.9e94.4]; geometric mean titer (GMT)Z 177.6 (95% CI:
153.2e206.0)} compared with the H5N1-DIL-groups [seroprotection ratesZ 5.0% (95% CI: 1.4
e12.3); GMTZ 6.3 (95% CI: 5.4e7.4)]. Immune response against the heterologous A/Indone-
sia/05/2005 strain was also stronger in the H5N1-AS03A-groups [seroprotection rateZ 45.6%
(95% CI: 40.0e51.4); GMTZ 20.5 (95% CI: 17.8e23.7)] compared with the H5N1-DIL groupshest Medicine, Department of Internal Medicine, 7 Chung-Shan South Road, Taipei 100, Taiwan.
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AS03A-adjuvanted H5N1 influenza vaccine 781[seroprotection rateZ 0.0% (95% CI: 0.0e4.5); GMTZ 5.0 (95% CI: 5.0e5.0)]. The overall reac-
togenicity profile of the adjuvanted formulations was clinically acceptable.
Conclusion: The AS03A-adjuvanted H5N1 influenza vaccine formulations induced stronger
immune response against the vaccine-homologous and heterologous strains than the nonadju-
vanted formulations. The AS03A-adjuvanted H5N1 vaccine demonstrated a good immunoge-
nicity and an acceptable safety profile in the Taiwanese population.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
In 2009, the H1N1 influenza virus emerged as the novel virus
affecting the worldwide human population.1 As of 16 May
2010, at least 18,097 deaths caused by H1N1 have been re-
ported in more than 214 countries.2 The World Health Orga-
nization (WHO) escalated the pandemic alert to phase 6 and
health authorities worldwide aimed at mitigating the large-
scale morbidity and mortality as well as the economic
impact of this pandemic. Therefore, in the current scenario,
the focus has shifted away from the H5N1 avian influenza
virus, which was previously considered to be the virus that
wouldpossibly cause thenext influenzapandemic.3 However,
the H5N1 virus continues to be a cause for concern because
not only does it have the ability to start a pandemic by itself,
but it can also combine with the H1N1 virus leading to
devastating effects.1
Since its re-emergence in 2003, the H5N1 virus has
caused sporadic outbreaks in humans with higher morbidity
and mortality rates than observed previously.1 This could
be indicative of the fact that the health impact in case of
a H5N1 influenza pandemic in the future is most likely to be
severe.1 As of 6 May 2010, 498 laboratory-confirmed cases
and 294 deaths caused by H5N1 influenza infection have
been recorded worldwide.4
To date, no cases of H5N1 influenza in humans or in
poultry have been recorded in Taiwan. However, Taiwan
has faced sporadic peaks in the incidence of seasonal
influenza.5 In addition, Taiwan also faces considerable
threat from the H5N1 virus considering that its neighbors
(China, Vietnam, Indonesia and Thailand) have recorded
a high number of laboratory-confirmed H5N1 cases (cumu-
lative: 347 cases and 237 deaths, as of 6 May 2010) and
a large number of foreign workers from these countries
travel to and reside in Taiwan.4
Timely vaccination is considered to be the most effec-
tive method of mitigating the morbidity and mortality
caused by an influenza pandemic.6 Anticipating limited
availability of influenza vaccine antigens and the potential
need to confer protection against the heterologous strains
derived from antigenic drifts and shifts, the WHO’s Stra-
tegic Advisory Group of Experts (SAGE) on immunization
acknowledged the importance of those influenza vaccines
formulated with oil-in-water-based adjuvants.7 Thus,
antigen-sparing through use of adjuvants and the ability to
induce immune response against heterologous strains are
the two essential parameters to evaluate the effectiveness
of any pandemic influenza vaccine.
GlaxoSmithKline Biologicals S.A. Belgium split-virion H5N1
influenza vaccine [hemagglutinin (HA) antigen content:3.75 mg] adjuvanted with AS03A [a tocopherol oil-in-water
emulsion-based adjuvant system (11.86 mg tocopherol)] is
in line with the SAGE recommendations. This vaccine has
been shown to be well tolerated and has elicited strong
immune response against the homologous A/Vietnam/1194/
2004 strain as well as against a heterologous A/Indonesia/
05/2005 strain in European populations.8,9
A study conducted in a large population across multiple
Asian centers in Taiwan, Singapore, Hong Kong and Thailand
demonstrated the vaccine’s ability to induce immune
response against the A/Vietnam/1194/2004 strain as well as
an immune response against the heterologous A/Indonesia/
05/2005 strain; the study also demonstrated manufacturing
consistency across paired formulations of HA antigen and
AS03A adjuvant. The overall results of this study have been
published previously.10 The current manuscript presents
Taiwan-specific data and compares it with the overall results.Materials and methods
Study design and subjects
This phase III, randomized study (NCT00449670) was con-
ducted between March 24 and July 12, 2007, across four
study regions in Asia (Taiwan, Singapore, Thailand and Hong
Kong). The study could not be double-blinded because of
the difference in appearance between the AS03A-adju-
vanted and nonadjuvanted formulations; hence, it was
observer-blinded. The study evaluated the manufacturing
consistency across four paired formulations (two lots of HA
antigen and two lots of AS03A adjuvant) of the AS03A-
adjuvanted split-virion H5N1 influenza vaccine in terms of
immune response against the vaccine-homologous A/Viet-
nam/1194/2004 strain. The vaccine’s ability to induce
immune response against a heterologous A/Indonesia/05/
2005 strain and safety of vaccine administration were also
evaluated.
In Taiwan, the study was conducted at the National
Taiwan University Hospital and Taipei Veterans General
Hospital. Eligible individuals aged between 18 and 60 years
were randomized (2:2:2:2:1:1 ratio) using a central
randomization scheme (SBIR), into six parallel study groupse
four adjuvanted vaccine groups and two nonadjuvanted
vaccine groups. People in the adjuvanted vaccine groups
(groups H5N1-AS03A) received two doses of one of the four
formulations of the AS03A-adjuvanted H5N1 split-virion
vaccine (two production lots of H5N1 3.75 mg HA antigen
mixed with two production lots of AS03A adjuvant) 21 days
apart. The people in the nonadjuvanted groups (groups
782 S.-J. Hwang et al.H5N1-DIL) received two doses of any one of the two formu-
lations of the nonadjuvanted H5N1 split-virion vaccine (two
production lots of H5N1 3.75 mg HA antigen mixed with
diluent) 21 days apart.
Volunteers were excluded if they had previously received
any licensed inactivated vaccine within 2 weeks or live-
attenuated vaccine within 4 weeks prior to enrollment in the
study, were likely to have been exposed to the H5N1 wild-
type virus, were allergic to vaccines or vaccine components,
had a confirmed or suspected immunosuppressive or immu-
nodeficient condition or were suffering from acute or chronic
infections. Lactating or pregnant women were also excluded
from the study.
The study protocols and associated study documents
were approved by the Independent Ethics Committees of
the participating centers and the Department of Health,
Executive Yuan in Taiwan. The study was conducted in
accordance with Good Clinical Practice guidelines and the
Declaration of Helsinki. Written informed consent was ob-
tained from subjects or their parents/guardians prior to
conducting any study-related procedures.
Vaccines
All formulations of the inactivated, split-virion AS03A-
adjuvanted influenza vaccine were manufactured by
GlaxoSmithKline Biologicals as described previously.8 Each
dose of vaccine (Prepandrix, 0.5 mL) contained at least
3.75 mg HA of the A/Vietnam/1194/2004-like NIBRG-14
Clade 1 strain (National Institute for Biological Standards
and Control Potters Bar, UK) adjuvanted with AS03A [a
tocopherol oil-in-water emulsion-based adjuvant system
(11.86 mg tocopherol)].8 All formulations were made avail-
able in multidose vials. Vaccines were administered intra-
muscularly in the deltoid region of the nondominant arm.
Laboratory assays
Serially diluted serum samples (initial dilution of 1:10,
followed by twofold serial dilution) were used to determine
the hemagglutination inhibition (HI) antibody titers using
standard techniques; however, modifications were done to
use an equine erythrocyte suspension instead of avian
erythrocytes, as described previously.8
Assessment of immunogenicity
Blood samples were collected before vaccination (Day 0)
and 21 days after each of the two vaccine doses to assess
geometric mean titers (GMT), seroprotection rates, sero-
conversion rates and seroconversion factors in terms of HI
antibodies against the homologous A/Vietnam/1194/2004
NIBRG-14 strain and heterologous A/Indonesia/05/2005
IBCDC-RG2 strain. The HI immune response evaluations
were based on the European Committee for Human
Medicinal Products (CHMP) immunogenicity guidance
criteria for pandemic influenza vaccines for adults aged
18e60 years: seroprotection rate >70.0%, seroconversion
rate >40.0% and seroconversion factor >2.5.11
The seroconversion rate for HI antibodies was defined as
the percentage of seronegative subjects (HI antibody titer<1:10) before vaccination with a postvaccination HI antibody
titer 1:40 or seropositive subjects (HI antibody titer 1:10)
before vaccination with at least a fourfold increase in HI
antibody titer, after each dose. The seroconversion factor
was defined as the fold increase in serum HI antibody GMTs
postvaccination compared to the GMT prior to Dose 1. The
seroprotection ratewasdefinedas the percentageof subjects
with a postvaccination serum HI antibody titer  1:40.
Assessment of safety and reactogenicity
Diary cards were provided to participants to record soli-
cited local and general adverse events up to 7 days after
each vaccination dose. Solicited local adverse events (pain,
redness, swelling, induration and ecchymosis) and general
adverse events (fatigue, fever, headache, myalgia, shiv-
ering, sweating and arthralgia) were recorded during the
7 days postvaccination follow-up period and were graded
on a scale of 0e3, except fever which was graded on a scale
of 0e4. Pain at injection site that hindered normal daily
activities was recorded as grade 3; injection site redness,
swelling, ecchymosis and induration> 100 mmwas recorded
as grade 3; fever > 39C and up to 40C was recorded as
grade 3,> 40C as grade 4; other solicited general symptoms
that hindered normal day-to-day activities were recorded as
grade 3 intensity. All unsolicited adverse events were
recorded up to 21 days after the first dose and 30 days after
the second dose. Serious adverse events (SAEs) were recor-
ded during the entire study period; events occurring until 30
days after the second dose are reported in this manuscript.
Statistical analyses
The analyses of immunogenicity were performed on the
per-protocol cohort, while the analyses of safety were
performed on the total vaccinated cohort. The per-protocol
cohort included people who had received at least one
dose of the adjuvanted or nonadjuvanted vaccine, were
compliant to the protocol and had available data for the
immunogenicity end points, while the total vaccinated
cohort included all vaccinated subjects with available data.
All statistical analyses were performed using SAS version
9.1 (SAS, North Carolina, USA). The 95% CIs for the group-
wise GMT ratio were calculated using the ANOVA model on
log-transformed titers, while all exact 95% CIs for propor-
tions within groups were calculated using Proc StatXact 5.0
(Cytel Inc., Massachusetts, USA).
Results
Study population
A total of 1206 individuals were enrolled across the four
study regions, of which 400 were enrolled in Taiwan (H5N1-
AS03A: NZ 319; H5N1-DIL: NZ 81). All individuals received
at least one vaccine dose and 391 people were included in
the per-protocol cohort for immunogenicity; reasons for
the exclusion of nine subjects from the per-protocol cohort
are presented in Fig. 1. The mean age of these 391 people
was 32.2 years (standard deviation: 8.71 years; range:
18e58 years). There were more females (57.8%) than males
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram for the study.
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one person was of South-East Asian origin).
Immunogenicity
This manuscript presents the pooled immunogenicity and
safety results from the H5N1-AS03A and H5N1-DIL groups.
HI antibodies against the homologous
A/Vietnam/1194/2004 strain:
Less than 3.0% of participants in the H5N1-AS03A and H5N1-
DIL groups had detectable levels of HI antibodies ( 1:10)
before vaccination. Following the second vaccine dose,
91.6% (95% CI: 87.9e94.4) of people in the H5N1-AS03A
groups were seroprotected (Table 1) and the HI antibody
GMTs for the A/Vietnam/1194/2004 strain increased
progressively from 5.2 (95% CI: 5.0e5.5) before vaccination
to 177.6 (95% CI: 153.2e206.0) after the second vaccine
dose (Fig. 1). However, in the H5N1-DIL group, after the
second vaccine dose, the seroprotection rate and HI anti-
body GMTs did not show an appreciable increase when
compared with the prevaccination status (Table 1, Fig. 1).
Twenty-one days after the second vaccine dose, the
CHMP immunogenicity guidance criteria were met for the
A/Vietnam/1194/2004 strain in the H5N1-AS03A groups.
None of the CHMP criteria was met in the H5N1-DIL groups.
HI antibodies against the heterologous
A/Indonesia/05/2005 strain:
Before vaccination, less than 0.5% of subjects in both
groups had detectable levels of HI antibodies ( 1:10).
Following the second vaccine dose, 45.6% (95% CI:Table 1 Seroprotection rate, seroconversion rate and seroconv
against the A/Vietnam/1194/2004 and A/Indonesia/05/2005 str
population (per-protocol cohort for immunogenicity).
Strains Parameters
(CHMP criteria for adult
A/Vietnam/ 1194/2004 NIBRG-14 Seroprotection rate> 7
Seroconversion rate> 4
Seroconversion factor >
A/Indonesia/ 05/2005 IBCDC-RG2 Seroprotection rate> 7
Seroconversion rate> 4
Seroconversion factor >
CHMPZ Committee for Human Medicinal Products; CIZ confidence i40.0e51.4) of individuals in the H5N1-AS03A group were
seroprotected (Table 1) and the HI antibody GMTs for the
A/Indonesia/05/2005 strain increased from 5.0 (95% CI:
5.0e5.0) before vaccination to 20.5 (95% CI: 17.8e23.7)
after the second vaccine dose (Fig. 1). In comparison, after
the second vaccine dose, none of the subjects in the H5N1-
DIL group were seroprotected (Table 1) and the HI anti-
body GMT for the A/Indonesia/05/2005 strain remained at
5.0 (95% CI: 5.0e5.0) (Fig. 1).
Twenty-one days after the second vaccine dose, two
of the three CHMP criteria (in terms of seroconversion
rate and seroconversion factor) for the heterologous
A/Indonesia/05/2005 strain were met in the H5N1-AS03A
groups. None of the CHMP criteria was met in the H5N1-DIL
groups (Fig. 2).
Safety and reactogenicity
A consistent trend towards higher incidence of solicited
local and general symptoms during the 7 days post-
vaccination follow-up period was observed in the H5N1-
AS03A groups compared to the H5N1-DIL groups. Pain at the
injection site [H5N1-AS03A: 96.2% (95% CI: 93.5e98.0);
H5N1-DIL: 37.0% (95% CI: 26.6e48.5)] and fatigue [H5N1-
AS03A: 75.2% (95% CI: 70.1e79.9); H5N1-DIL: 44.4% (95%
CI: 33.4e55.9)] were the most frequently reported solicited
local and general symptoms, respectively, in both groups.
Grade 3 pain and fatigue were reported by 4.7% (95% CI:
2.7e7.6) and 5.3% (95% CI: 3.1e8.4) subjects, respectively,
in the H5N1-AS03A groups. None of the participants in the
H5N1-DIL groups reported solicited local or general symp-
toms of grade 3 intensity. The occurrence and intensity ofersion factor for H5N1 hemagglutination inhibition antibodies
ains 21 days after the second vaccine dose for Taiwanese
s)
H5N1-AS03A NZ 309%
(95% CI)
H5N1-DIL NZ 80%
(95% CI)
0.0% 91.6% (87.9e94.4) 5.0% (1.4e12.3)
0.0% 90.9% (87.2e93.9) 3.8% (0.8e10.6)
2.5 33.9 (29.1e39.3) 1.2 (1.0e1.4)
0.0% 45.6% (40.0e51.4) 0.0% (0.0e4.5)
0.0% 45.6% (40.0e51.4) 0.0% (0.0e4.5)
2.5 4.1 (3.5e4.7) 1.0 (1.0e1.0)
nterval.
Figure 2 Geometric mean titers (GMTs) for H5N1 hemagglutination inhibition antibodies against A/Vietnam/1194/2004 and
A/Indonesia/05/2005 strains, prevaccination and 21 days after each vaccine dose for Taiwanese population (per-protocol cohort for
immunogenicity). aError bars indicate 95% confidence intervals for each group.
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Table 2.
The occurrence of at least one unsolicited symptom was
reported by 39.8% (95% CI: 34.4e45.4) of individuals in the
H5N1-AS03A groups and 29.6% (95% CI: 20e40.8) of individ-
uals in the H5N1-DIL groups. Unsolicited symptoms consid-
ered by the investigator to be causally related to vaccination
were reported by 12.2% (95% CI: 8.8e16.3) of individuals in
the H5N1-AS03A groups (39 subjects) and 2.5% (95% CI:
0.3e8.6) of individuals in the H5N1-DIL groups (two people).
Dizziness was the most commonly reported unsolicited
adverse event [2.8% (95% CI: 1.3e5.3); nine individuals] in
the H5N1-AS03A groups, while in the H5N1-DIL groups,
abdominal pain, nausea and pharyngeal pain [1.2% (95% CI:
0e6.7) of each; one participant each) were most commonly
reported. Only 0.3% (95% CI: 0e1.7) of people in the H5N1-
AS03A groups (one person) reported vaccine-related grade
3 unsolicited adverse events; this person reported asthenia,
dizziness and lethargy. No vaccine-related grade 3 unsolic-
ited adverse events were recorded in the H5N1-DIL groups.
During the entire study, three SAEs were recorded in
three participants, all in the H5N1-AS03A groups. None of
these, namely hand injury (fracture of the radius), acute
appendicitis and leiomyoma of uterus, were considered by
the investigators to be vaccine related. All three subjects
recovered by the end of the study.Discussion
At the onset of an influenza pandemic, the immediate
availability of a large number of doses of immunogenic
influenza vaccine with acceptable reactogenicity profile is
of paramount importance. In addition, considering that thestrain causing the pandemic in all probability could be
a new strain arising from antigenic drifts or shifts in existing
strains, the ability of a pandemic influenza vaccine to
induce immune response against heterologous strains could
be critical in limiting the spread of the virus. Hence, in
addition to evaluating nonadjuvanted candidates, current
vaccine development initiatives are also focusing on adju-
vanted vaccines that can be both antigen sparing and can
induce immune response against heterologous strains in
addition to the vaccine strain.6
In this context, the split-virion H5N1 influenza vaccine
approved by the US Food and Drug Administration (FDA) in
2007 has limitations with respect to both antigen-sparing
and heterologous strain seroprotection.12,13
The Taiwan-specific data from the present study re-
established the observations from the overall Asian pop-
ulation that the use of AS03A adjuvant can influence the
immune responses elicited by the H5N1 vaccines; this was
evident from the stronger immune response mounted by
the individuals who received the AS03A-adjuvanted H5N1
influenza vaccine compared to those who received the
nonadjuvanted H5N1 influenza vaccine. All three CHMP
criteria, were met and exceeded in subjects in the
H5N1-AS03A group for the homologous A/Vietnam/1194/
2004 strain, while two of the three CHMP criteria were met
for the heterologous A/Indonesia/05/2005 strain.11 In
comparison, none of the CHMP criteria for either of the
strains was met in subjects who received the non-
adjuvanted H5N1 influenza vaccine. The immune response
was further evaluated in a subset of subjects from the four
study centers using a broader andmore sensitive neutralizing
assay which demonstrated a higher seroconversion rate
for the A/Vietnam/1194/2004 and A/Indonesia/05/2005
strains in the H5N1-AS03A groups (Day 42; A/Vietnam: 96%;
Table 2 Solicited local and general adverse events recorded in the H5N1-AS03 and H5N1-DIL groups during the 7-day
postvaccination follow-up period for Taiwanese population (total vaccinated cohort).
Symptoms Severity H5N1-AS03A
% (95% CI)
H5N1-DIL
% (95% CI)
Local symptoms Ecchymosis All 1.6 (0.5e3.6) 0.0 (0.0e4.5)
Grade 3 0.0 (0.0e1.1) 0.0 (0.0e4.5)
Induration All 8.2 (5.4e11.7) 0.0 (0.0e4.5)
Grade 3 0.0 (0.0e1.1) 0.0 (0.0e4.5)
Pain All 96.2 (93.5e98.0) 37.0 (26.6e48.5)
Grade 3 4.7 (2.7e7.6) 0.0 (0.0e4.5)
Redness All 6.3 (3.9e9.5) 1.2 (0.0e6.7)
Grade 3 0.0 (0.0e1.1) 0.0 (0.0e4.5)
Swelling All 14.4 (10.8e18.8) 0.0 (0.0e4.5)
Grade 3 0.3 (0.0e1) 0.0 (0.0e4.5)
General symptoms Arthralgia All 22.3 (17.8e27.2) 9.9 (4.4e18.5)
Grade 3 0.9 (0.2e2.7) 0.0 (0.0e4.5)
Fatigue All 75.2 (70.1e79.9) 44.4 (33.4e55.9)
Grade 3 5.3 (3.1e8.4) 0.0 (0.0e4.5)
Fever All 2.8 (1.3e5.3) 0.0 (0.0e4.5)
Grade 3 0.0 (0.0e1.1) 0.0 (0.0e4.5)
Headache All 43.3 (37.8e48.9) 19.8 (11.7e30.1)
Grade 3 3.4 (1.7e6.1) 0.0 (0.0e4.5)
Myalgia All 74.0 (68.8e78.7) 30.9 (21.1e42.1)
Grade 3 4.1 (2.2e6.9) 0.0 (0.0e4.5)
Shivering All 9.1 (6.2e12.8) 1.2 (0.0e6.7)
Grade 3 0.6 (0.1e2.2) 0.0 (0.0e4.5)
Sweating All 16.0 (12.1e20.5) 6.2 (2.0e13.8)
Grade 3 0.0 (0.0e1.1) 0.0 (0.0e4.5)
CIZ confidence interval.
AS03A-adjuvanted H5N1 influenza vaccine 785A/Indonesia: 91.4%) compared to the H5N1-DIL groups (Day
42; A/Vietnam: 32.4%; A/Indonesia: 5.6%).10 The vaccine
was well tolerated in the Taiwanese population with no
additional noticeable difference in the safety and reac-
togenicity profile being reported when compared to the
overall study as well as to studies conducted in other
populations.8e10,14 Thus, the results of this study contribute
to the existing literature on the good immunogenicity and
acceptable safety data on the AS03A-adjuvanted H5N1
influenza vaccine.
The Government of Taiwan has formulated and imple-
mented its Influenza Pandemic Preparedness Plan with the
aim to facilitate mitigation of an impending influenza
pandemic,5 and in this context, these Taiwan-specific data
on the study vaccine are of critical importance.
This manuscript focused exclusively on the Taiwanese
population to present relevant data that would be of critical
importance to the healthcare authorities and decision-
makers in Taiwan in the light of the continuing threat of
the H5N1 influenza strain in the region. However, a possible
weakness of this manuscript is that the Taiwanese study
population included 400 subjects which is a comparatively
smaller sample size when compared to the overall multi-
center study that included 1206 participants. This sample
size also did not allow for age-wise stratification. Never-
theless, ample evidence can be drawn from available
literature on the safety and immunogenicity of this AS03A-
adjuvanted H5N1 vaccine.
In conclusion, the AS03A-adjuvanted split-virion H5N1
vaccine was well tolerated and allowed antigen-sparingas observed from a stronger immune response not only
against the homologous H5N1 vaccine strain but also
against a heterologous H5N1 strain as compared to the
nonadjuvanted formulation, with the same antigen content.
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